Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 333-335

  Baxter, T ^a   Eadie, C J ^b  

^a Schwarz Pharma   (United Kingdom)

^b Data Analysis and Research Ltd   (United Kingdom)

Author keywords

angina pectoris; isosorbide mononitrate; once daily sustained release formulation; plasma profile

Indexed keywords

ISOSORBIDE 5 NITRATE; ISOSORBIDE MONONITRATE;

ADULT; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; VOLUNTEER;

EID: 0031044247     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00563.x     Document Type: Article

References (2)

1. Davies W. Pharmacokinetics and relative bioavailability of ISMN after chronic oral dose administration of 2 formulations (Elantan tablets vs Elantan long (LA50) capsules). Mononitrates 4 Workshop Kronberg, March 1985; 13-19.
2. Inveresk Research International: Internal Report Number 10603.